Summit (SMMT) PD-1·VEGF Bispecific Antibody Ivonescimab Fails Phase 3 Interim Analysis, Shares Plummet
Heightened Statistical Barriers and Expanding Market Volatility
Summit Therapeutics (SMMT)'s PD-1·VEGF bispecific antibody Ivonescimab (AK112) in the global Phase 3 trial (HARMONi-3) posted interim results that fell short of market expectations. The study is being conducted as a head‑to‑head comparison against Merck (MRK) Keytruda in the first‑line setting for squamous non‑small cell lung cancer (NSCLC). The interim analysis failed to demonstrate a statistically significant improvement in progression‑free survival (PFS), prompting Summit’s share price to drop more than 25% on the day of the announcement. However, the independent data monitoring committee (IDMC) recommended that the trial continue as planned, and the industry is interpreting the event as a temporary market concern driven by a potential delay in early commercialization timelines.
Conservative Alpha‑Spending Design Led to Missed Endpoint
Analysts attribute the miss primarily to an overly conservative statistical design rather than to the drug’s intrinsic efficacy. The interim analysis was allocated an alpha‑spending level of roughly 0.001, preserving almost the entire significance threshold for the final analysis, which set a very high barrier for demonstrating significance at the interim look. Citi and other analysts note that the shortfall may be a temporary artifact of insufficient accumulated PFS events, and that the bulk of the alpha remains intact for the final analysis, leaving a substantial chance of ultimate success. In short, the aggressive interim‑analysis option pursued to accelerate approval backfired, triggering a short‑term share price plunge.
Chinese Clinical Data as a Test of Global Replicability
The outcome reignites questions about whether the efficacy demonstrated by Akeso (HKG: 9926) in its China‑only Phase 3 program can be replicated in a broader global population. In the Chinese HARMONi‑2 trial, Ivonescimab improved PFS by 49% versus Keytruda, and in HARMONi‑6 it showed a 40% PFS advantage over BeiGene’s Tevimbra. However, moving into a global Phase 3 with a majority of Western patients raises concerns that the magnitude of benefit may attenuate. Demonstrating that Ivonescimab can overcome ethnic variability and become a global standard of care is the pivotal challenge of this trial.
H2 2026 Final Analysis and the $5 B Deal’s Outcome
Summit remains focused on delivering the final PFS and overall survival (OS) readouts expected in the second half of 2026 without altering the trial design. The Chinese Phase 3 (HARMONi‑6) OS data have been selected for a plenary oral presentation at the American Society of Clinical Oncology (ASCO), making the results a potential catalyst to allay global concerns. If the data confirm a survival benefit, the $5 billion license‑in agreement (including a $500 million upfront payment) that Summit signed with Akeso in December 2022 for North American, European and Japanese rights to Ivonescimab could finally be validated.
The lack of statistically significant interim results for Summit Therapeutics’ (SMMT) bispecific antibody Ivonescimab in the global Phase 3 HARMONi‑3 trial represents a short‑term setback that could delay accelerated approval pathways. However, because the majority of the alpha for the final PFS analysis remains intact, the opportunity to demonstrate superiority over Merck’s (MRK) Keytruda in the roughly $31 billion global first‑line NSCLC market by 2026 remains viable. Industry observers will watch closely whether the 40‑49% PFS gains observed in the Chinese HARMONi‑2 and HARMONi‑6 studies can be reproduced in multinational trials, as this will be a key indicator of the bispecific platform’s commercial potential. In the medium to long term, the final PFS and overall survival data expected in H2 2026 will determine the drug’s valuation and the likelihood of receiving up to $4.5 billion in remaining milestone payments.
Source: FierceBiotech (rss)